NOVAVAX ANNOUNCES INFLUENZA VACCINE PRECLINICAL RESULTS

Novavax has received positive results from several preclinical studies relating to the company's pandemic and seasonal influenza vaccines, which are in development.

Scientists at the University of Pittsburgh and the Southern Research Institute in Birmingham, Ala., have been collaborating with Novavax to test the company's virus-like particle (VLP) vaccines for various strains of influenza.

Using the company's proprietary VLP technology, Novavax scientists create a particle that is nearly identical to a virus but does not have the virus's genetic material required for replication or infection. When injected into the body, these particles have the ability to attach to cells and trigger a natural immune response that is capable of protecting against viral infection.